Milton Ault III Sells 65,903 Shares of Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 65,903 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $2.44, for a total transaction of $160,803.32. Following the sale, the director directly owned 8,260 shares in the company, valued at $20,154.40. This represents a 88.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Alzamend Neuro Stock Up 2.4%

Shares of ALZN opened at $2.53 on Monday. Alzamend Neuro, Inc. has a fifty-two week low of $2.06 and a fifty-two week high of $17.10. The firm’s 50 day moving average price is $2.40 and its 200 day moving average price is $4.05.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ALZN shares. Ascendiant Capital Markets cut their price objective on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, September 25th. Wall Street Zen downgraded Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Alzamend Neuro in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $42.00.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.